PT  - JOURNAL ARTICLE
AU  - Gutierrez, Bernardo
AU  - Márquez, Sully
AU  - Prado-Vivar, Belén
AU  - Becerra-Wong, Mónica
AU  - Guadalupe, Juan José
AU  - da Silva Candido, Darlan
AU  - Fernandez-Cadena, Juan Carlos
AU  - Morey-Leon, Gabriel
AU  - Armas-Gonzalez, Rubén
AU  - Andrade-Molina, Derly Madeleiny
AU  - Bruno, Alfredo
AU  - de Mora, Domenica
AU  - Olmedo, Maritza
AU  - Portugal, Denisse
AU  - Gonzalez, Manuel
AU  - Orlando, Alberto
AU  - Drexler, Jan Felix
AU  - Moreira-Soto, Andres
AU  - Sander, Anna-Lena
AU  - Brünink, Sebastian
AU  - Kühne, Arne
AU  - Patiño, Leandro
AU  - Carrazco-Montalvo, Andrés
AU  - Mestanza, Orson
AU  - Zurita, Jeannete
AU  - Sevillano, Gabriela
AU  - du Plessis, Louis
AU  - McCrone, John T.
AU  - Coloma, Josefina
AU  - Trueba, Gabriel
AU  - Barragán, Verónica
AU  - Rojas-Silva, Patricio
AU  - Grunauer, Michelle
AU  - Kraemer, Moritz U.G.
AU  - Faria, Nuno R.
AU  - Escalera-Zamudio, Marina
AU  - Pybus, Oliver G.
AU  - Cárdenas, Paúl
TI  - Genomic epidemiology of SARS-CoV-2 transmission lineages in Ecuador
AID  - 10.1101/2021.03.31.21254685
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.31.21254685
4099  - http://medrxiv.org/content/early/2021/04/05/2021.03.31.21254685.short
4100  - http://medrxiv.org/content/early/2021/04/05/2021.03.31.21254685.full
AB  - Characterisation of SARS-CoV-2 genetic diversity through space and time can reveal trends in virus importation and domestic circulation, and permit the exploration of questions regarding the early transmission dynamics. Here we present a detailed description of SARS-CoV-2 genomic epidemiology in Ecuador, one of the hardest hit countries during the early stages of the COVID-19 pandemic. We generate and analyse 160 whole genome sequences sampled from all provinces of Ecuador in 2020. Molecular clock and phylgeographic analysis of these sequences in the context of global SARS-CoV-2 diversity enable us to identify and characterise individual transmission lineages within Ecuador, explore their spatiotemporal distributions, and consider their introduction and domestic circulation. Our results reveal a pattern of multiple international importations across the country, with apparent differences between key provinces. Transmission lineages were mostly introduced before the implementation of non-pharmaceutical interventions (NPIs), with differential degrees of persistence and national dissemination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by the Clarendon Fund and the Department of Zoology of the University of Oxford (D.S.C.); WT fellowship 204311/Z/16/Z and MRC-FAPESP awards MR/S0195/1 and 18/14389-0 (N.R.F.); Branco Weiss Fellowship and EU grant 874850 MOOD (M.U.G.K.); WT Collaborators Award 206298/Z/17/Z (J.T.M.); Leverhulme Trust ECR Fellowship ECF-2019-542 (M.E.Z.); the Oxford Martin School (O.G.P., M.U.G.K. and L.d.P.); and the NIH Global Health Equity Scholars award FIC D43TW010540 (P.C.). Additional funding was provided for sample sequencing by the USFQ Emergency Grants, the A2CARES Network and the Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CEISH-USFQ 255 (Comite de Etica de Investigacion en Seres Humanos-USFQ): IE-JP067-2020-CEISH-256 USFQ; Ministerio de Salud Publica Comite Expedito (021-2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe newly generated sequences have been publicly shared through the GISAID platform. The data sets (including Ministry of Health and National Institute of Statistics and Census data) and code used to generate the analyses presented in this study, as well as a list of accession numbers for the Ecuador SARS-CoV-2 genome sequences analysed here are available through GitHub at https://github.com/BernardoGG/SARS-CoV-2_Genomic_lineages_Ecuador. We thank Andres N. Robalino and Carlos Oporto for their contribution to the open licence Ecuacovid repository (https://github.com/andrab/ecuacovid) used to extract epidemiological data for this study.https://github.com/BernardoGG/SARS-CoV-2_Genomic_lineages_Ecuadorhttps://github.com/andrab/ecuacovid